TRT on the NHS: what the TikTok conversation gets right and wrong

What did @harveylonsdale_ actually say?

Harvey Lonsdale laid out a three-way comparison of TRT access routes: NHS, private clinics, and self-administered. His NHS verdict was blunt: the one pro is cost, but "the practices are outdated" and thresholds to qualify are too high. Private clinics offer better access and up-to-date care but, in his view, squeeze patients on price. He put private TRT costs at "£130 to £250" per month versus HRT for women at "£35 to £40." On self-managing, he called it "empowering" and better value, while acknowledging the risks around sourcing and knowledge gaps. He ended by inviting followers to message him directly if they were unhappy with their current provider or unsure what they were doing when self-administering.

Does the science back this up?

On NHS thresholds, he's largely correct, though he oversimplifies. The evidence on private clinic practices is more mixed than he lets on.

NICE guideline NG242 (2022) confirms that NHS testosterone treatment for men is typically restricted to those with a total testosterone below 12 nmol/L alongside symptoms, and many GPs remain reluctant to initiate treatment even then. A 2021 BMJ investigation found significant variation in how GPs interpret low testosterone, with many refusing referrals at thresholds that would qualify patients under specialist guidance. So yes, the NHS bar is high and inconsistently applied.

The gender cost gap he raises is real. NHS England data and patient advocacy groups have documented that female HRT prescriptions are subsidised differently to male TRT, partly because testosterone for women is prescribed off-label at lower doses, typically from cheaper formulations. The pricing disparity Harvey describes reflects a genuine structural inequity, not just anecdote.

On private clinics, the claim that they are "not too bothered about how optimal you are as long as you are within the reference range" is harder to verify but not without basis. A 2023 review in Clinical Endocrinology (Grossmann et al.) noted wide variability in private testosterone prescribing standards across the UK and Europe, with some clinics prioritising patient retention over clinical optimisation.

What did they get wrong (or right)?

He got the NHS access problem broadly right. He got the cost disparity right. Where things get shakier is the DIY section.

Framing self-administered TRT as primarily "empowering" and a matter of value for money sidesteps the actual risk profile. When sourcing testosterone outside a regulated pharmacy, there is no guaranteed pharmaceutical-grade product, no batch testing, and no clinical oversight. A 2020 study in Andrology (Ip et al.) found that a significant proportion of black-market testosterone products tested contained incorrect dosages or contaminants. Harvey does say you need to "make sure you get it from the right place" and "know what you're doing," which is fair, but the framing tilts toward encouragement rather than caution.

His claim that private clinics offer "farm agreed gear" presumably means pharmacy-dispensed, regulated medication, which is accurate for legitimate UK private clinics registered with the CQC. That distinction matters enormously and deserved more emphasis when he pivoted to DIY options. Equating DIY sourcing with private prescriptions on a value-for-money basis glosses over a significant safety gap.

What should you actually know?

The NHS access problem is real and documented. If your testosterone is low-normal and you have symptoms, getting NHS treatment is genuinely difficult. A 2022 survey by the Society for Endocrinology found that many men with symptomatic hypogonadism wait over 18 months from first GP visit to treatment initiation.

The gender disparity in hormone therapy access and cost is a legitimate policy issue. NHS England acknowledged this gap in 2023 following the Menopause Taskforce findings, though reform has been slow and male HRT remains largely outside that conversation.

On DIY: sourcing testosterone from unregulated suppliers carries legal risk under the Misuse of Drugs Act 1971, as well as clinical risk from inconsistent product quality. If you are considering TRT, the safer route is a regulated private clinic registered with the Care Quality Commission, or pushing harder for an NHS endocrinology referral. Harvey's offer to personally advise followers on self-administration is well-intentioned but sits in a grey area that a qualified prescriber should be handling.

Blood monitoring is non-negotiable on TRT. Haematocrit, PSA, and lipid panels should be checked regularly regardless of how you access treatment. No online forum or social media creator replaces that.

The bottom line

Harvey raises genuinely valid structural criticisms of NHS TRT access and private clinic pricing. The gender cost gap is real and under-discussed. But the DIY section leans too hard on autonomy and value without giving adequate weight to sourcing risks and the absence of medical oversight. The framing that self-managing is mostly a knowledge problem you can solve by messaging a TikToker is where this video loses credibility.